For the quarter ending 2025-09-30, ARQT had -$25,620K decrease in cash & cash equivalents over the period. -$1,754K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Loss from operations | - | - | - | -128,397 |
| Other income, net | - | - | - | 16,173 |
| Interest expense | - | - | - | 27,168 |
| Provision for income taxes | - | - | - | 647 |
| Net loss | 7,410 | -15,886 | -25,060 | -10,788 |
| Depreciation | - | - | 153 | 145 |
| Non-cash lease expense | - | - | 111 | 107 |
| Stock-based compensation expense | 10,037 | 10,489 | 9,778 | 9,393 |
| Amortization of intangible assets | 562 | 563 | 2,979 | 313 |
| Acquired in-process research and development | - | - | - | 0 |
| Non-cash interest expense | 449 | 431 | 415 | 2,595 |
| Net accretion on marketable securities | 551 | 695 | 859 | 1,096 |
| Changes in fair value of embedded derivative instrument | - | - | 210 | -150 |
| Other non-cash items, net | -283 | -348 | - | - |
| Accounts receivable, net | 8,429 | 21,272 | 12,349 | 14,126 |
| Inventories | 5,891 | -518 | 1,951 | 265 |
| Prepaid expenses and other current assets | 1,760 | -4,300 | 3,282 | 66 |
| Accounts payable | -9,288 | 554 | 309 | -105 |
| Accrued liabilities | 5,574 | 21,232 | -214 | 13,183 |
| Operating lease liabilities | -150 | -204 | -200 | -188 |
| Net cash used in operating activities | -1,754 | 324 | -30,380 | -748 |
| Purchases of marketable securities | 68,544 | 33,152 | 56,110 | 17,399 |
| Acquisition of in-process research and development | - | - | - | 0 |
| Proceeds from maturities of marketable securities | 43,297 | 60,653 | 68,468 | 57,276 |
| Milestone payment for intangible asset | 0 | 10,000 | - | 5,000 |
| Purchases of property and equipment | 0 | 78 | 608 | 0 |
| Repayment of long-term debt | - | - | - | 100,000 |
| Net cash provided by (used in) investing activities | -25,247 | 17,423 | 11,750 | 34,877 |
| Proceeds from issuance of common stock upon exercise of stock options | 1,476 | 61 | 395 | 1,525 |
| Proceeds from issuance of common stock pursuant to employee stock purchase plan | 0 | 1,319 | - | 1,064 |
| Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs | - | - | - | 0 |
| Proceeds from long-term debt | - | - | - | 0 |
| Proceeds from issuance of shares under atm, net of issuance costs | - | - | - | 0 |
| Payment of debt issuance costs | - | - | - | 0 |
| Proceeds from issuance of common stock, net of issuance costs | 0 | 0 | 0 | 0 |
| Net cash provided by financing activities | 1,476 | 1,380 | 395 | -97,411 |
| Effect of exchange rate changes on cash | -95 | 200 | 4 | -234 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -25,620 | 19,327 | -18,231 | -63,516 |
| Cash and cash equivalents at beginning of period | 73,048 | 53,721 | 71,952 | 135,468 |
| Cash and cash equivalents at end of period | 47,428 | 73,048 | 53,721 | 71,952 |
Arcutis Biotherapeutics, Inc. (ARQT)
Arcutis Biotherapeutics, Inc. (ARQT)